Chinese researchers and neurotechnology startups are accelerating the development of brain-computer interfaces (BCIs) that can be implanted in a matter of minutes, bypassing the need for highly invasive brain surgery. This rapid commercialization push aligns with Beijing’s strategic directive to nurture homegrown champions in the neurotechnology sector, capable of competing directly with high-profile Western ventures, such as Elon Musk’s Neuralink. The emerging Chinese devices allow patients to control digital technology using only their thoughts, but utilize a radically different, minimally invasive delivery mechanism.
According to the South China Morning Post, the new generation of Chinese BCIs can be inserted via a vein, functioning similarly to a cardiovascular stent. StairMed Technology, a prominent Shanghai-based startup, is at the forefront of this effort. Speaking at the Global Health Summit in Hong Kong, StairMed co-founder Zhao Zhengtuo explained that the company is “developing a more minimally invasive way of delivering the device, entering through blood vessels in the neck and guiding it through the vascular system directly into the brain.”
This approach contrasts sharply with conventional BCI systems, which typically require neurosurgeons to drill through the skull and penetrate brain tissue to place electrode arrays. By utilizing the body’s existing vascular network, the Chinese approach significantly reduces surgical risks, recovery times, and the potential for long-term tissue scarring, making the technology accessible to a much broader patient population.
Minimally Invasive Surgical Delivery
The surgical efficiency of the vascular approach is a major selling point for clinical adoption. Duan Wanru, a researcher from Xuanwu Hospital, noted that “a surgeon with four or five years of experience can position the device in as little as 10 minutes.” This streamlined procedure dramatically lowers the barrier to entry for hospitals and clinics, potentially allowing the technology to scale far more rapidly than systems requiring specialized neurosurgical expertise and extended operating room time.
StairMed has secured substantial financial backing to advance its clinical pipeline. The firm has raised more than 1.1 billion yuan ($163 million) in funding over the past year. Notably, its investor syndicate includes major Chinese technology conglomerates Tencent Holdings and Alibaba Group Holding, indicating strong strategic interest from the country’s digital giants in the future of neural interfaces.
In December, StairMed formally unveiled its vascular BCI program, undertaken in partnership with a research team at the Chinese Academy of Sciences. The technique involves navigating the device through a blood vessel into a targeted region of the brain and anchoring it in place outside the vessel wall, where it can record neural activity without directly touching the brain parenchyma. The company has successfully tested the technique on sheep and is preparing to advance toward human clinical trials.
Strategic Competition in Neurotechnology
The race to commercialize BCI technology is intensifying globally, driven by the immense potential to treat severe neurological conditions and eventually augment human cognitive capabilities. The BCI implant device market is projected to experience explosive growth over the next decade. According to a Morgan Stanley report, the market could be worth $80 billion in the United States alone by 2035.
Recognizing the strategic importance of this emerging field, the Chinese government has made neurotechnology a national priority. Beijing has vowed to nurture “two or three” global players in the BCI sector by 2030, providing robust regulatory support and funding channels to accelerate domestic research and development. This state-backed push is designed to ensure that China is not reliant on foreign technology for critical medical and human-augmentation systems in the future.
The competition with Western firms like Neuralink is not merely about market share, but about defining the dominant technological architecture for neural interfaces. While Neuralink focuses on high-bandwidth, tissue-penetrating electrodes inserted by robotic surgeons, the Chinese emphasis on minimally invasive, stent-like devices prioritizes safety, rapid deployment, and broader clinical accessibility.
Both approaches have distinct advantages and technical hurdles, and the ultimate winner may depend on which architecture achieves widespread regulatory approval and patient acceptance first.
Broadening Clinical Applications
The immediate focus for these BCI devices is therapeutic, targeting patients with severe motor impairments, spinal cord injuries, or neurodegenerative diseases like ALS. By translating neural intentions into digital commands, the technology allows paralyzed individuals to operate computers, communicate, and control robotic prosthetics or wheelchairs. The minimally invasive nature of the vascular approach makes it a particularly attractive option for frail patients who might not survive conventional open-brain surgery.
Beyond therapeutic applications, the long-term vision for BCI technology encompasses broader human-computer integration. As the devices become safer, more reliable, and capable of higher-bandwidth data transfer, they could eventually be used by healthy individuals to interact seamlessly with digital environments, virtual reality systems, and artificial intelligence agents. The rapid development of BCI hardware in China is occurring in parallel with the country’s massive investments in generative AI, creating the foundation for a deeply integrated technological ecosystem.
For the global medical technology industry, the rapid progress of Chinese BCI startups signals a shift in the center of gravity for neuro-engineering. By combining aggressive venture funding, state-level strategic support, and innovative surgical approaches, companies like StairMed are positioning themselves as formidable competitors on the world stage. The success of their upcoming human trials will be a critical milestone, potentially establishing the vascular delivery method as the new global standard for neural interface implantation.